Dataset related to article "Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience"
Creators
- Fargnoli, Maria Concetta1
- Esposito, Maria2
- Dapavo, Paolo3
- Parodi, Aurora4
- Rossi, Mario5
- Tiberio, Rossana6
- Dastoli, Stefano7
- Offidani, Anna Maria8
- Argenziano, Giuseppe9
- Gisondi, Paolo10
- Lo Schiavo, Ada11
- Loconsole, Francesco11
- Pella, Paolo12
- Bardazzi, Federico13
- Cusano, Francesco14
- Gattoni, Maurizio15
- Nacca, Mauro15
- Cannavo', Serafinella Patrizia16
- Costanzo, Antonio17
- 1. Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
- 2. ASO City of Health and Science, University Dermatological Clinic, Torino, Italy
- 3. Dermatologia, Ospedale S.G. Battista Molinette, Torino, Italy
- 4. Clinica Dermatologica, DiSSal University of Genoa, Ospedale-Policlinico San Martino IRCCS, Genoa, Italy
- 5. Dermatologia, ASST Spedali Civili Brescia, Brescia, Italy
- 6. Clinica Dermatologica, AOU Maggiore della Carità, Novara, Italy.
- 7. Dermatologia, Azienda Ospedaliera Universitaria 'Mater Domini', Catanzaro, Italy.
- 8. Clinica Dermatologica, Azienda Ospedaliero-Universitaria 'Ospedali Riuniti Ancona', Ancona, Italy.
- 9. Dermatology Unit, University of Campania, Naples, Italy
- 10. Clinica Dermatologica, Ospedale Civile Maggiore Borgo Trento, Verona, Italy
- 11. Clinica Dermatologica, Azienda Ospedaliera Universitaria Policlinico Bari, Bari, Italy.
- 12. Dermatologia, Ospedale degli Infermi, Biella, Italy
- 13. Department of Experimental, Diagnostic and Specialty Medicine, Division of Dermatology, University of Bologna, Bologna, Italy.
- 14. Unità Operativa Complessa di Dermatologia, Azienda Ospedaliera San Pio, Benevento, Italy.
- 15. Department of Dermatology, S. Andrea Hospital, Vercelli, Italy.
- 16. Dermatology, University Hospital 'G. Martino', Messina, Italy.
- 17. Dermatology Unit, Humanitas University, Pieve Emanuele, Italy AND Skin Pathology Laboratory, IRCCS Humanitas Research Hospital, Rozzano, Italy
Description
This record contains raw data related to article “Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience"
Background: Brodalumab was efficacious and safe in moderate-to-severe plaque-type psoriasis in the AMAGINE trials; published reports under real-life conditions are limited.
Objectives: To evaluate the effectiveness and safety of brodalumab in patients with moderate-to-severe plaque-type psoriasis in a real-world setting.
Methods: This observational, retrospective study enrolled adult patients (≥18 years) with moderate-to-severe plaque-type psoriasis who underwent 24 weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded.
Results: Seventy-eight patients (mean age 47.9 years, 71.8% male, average disease duration 16.8 years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4 weeks of treatment, decreasing further at weeks 12 and 24 (all P < 0.0001 vs. baseline). A higher number of cardiometabolic comorbidities and previous therapies were negatively associated with the achievement of PASI 90 at all assessments. Brodalumab was effective in bio-experienced patients, including those who had failed on anti-interleukin (IL)-17 therapies. Quality of life and patient satisfaction increased significantly during treatment (P < 0.0001 and P < 0.01 vs. baseline, respectively). Treatment was interrupted in 9 (11.5%) patients due to adverse events (n = 4), lack of efficacy (n = 3), lost to follow-up (n = 1) and surgical procedure (n = 1).
Conclusions: Brodalumab is effective and safe in the treatment of moderate-to-severe psoriasis in a real-world setting, including in patients with failure to anti-IL17 therapies.
Files
Restricted
The record is publicly accessible, but files are restricted to users with access.
Request access
If you would like to request access to these files, please fill out the form below.
You need to satisfy these conditions in order for this request to be accepted:
This set of data is accessible only upon request because it includes sensitive data. Please write your request to biblioteca@humanitas.it
You are currently not logged in. Do you have an account? Log in here
Additional details
Related works
- Is supplement to
- 10.1111/jdv.16931 (DOI)
- 32916767 (PMID)